• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从不吸烟的亚洲女性肺癌是由致癌突变驱动的,其中最常见的是涉及表皮生长因子受体(EGFR)。

Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR.

作者信息

Ha Sang Yun, Choi So-Jung, Cho Jong Ho, Choi Hye Joo, Lee Jinseon, Jung Kyungsoo, Irwin Darry, Liu Xiao, Lira Maruja E, Mao Mao, Kim Hong Kwan, Choi Yong Soo, Shim Young Mog, Park Woong Yang, Choi Yoon-La, Kim Jhingook

机构信息

Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Oncotarget. 2015 Mar 10;6(7):5465-74. doi: 10.18632/oncotarget.2925.

DOI:10.18632/oncotarget.2925
PMID:25760072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4467161/
Abstract

The aim of this study was to determine the distribution of known oncogenic driver mutations in female never-smoker Asian patients with lung adenocarcinoma. We analyzed 214 mutations across 26 lung cancer-associated genes and three fusion genes using the MassARRAY LungCarta Panel and the ALK, ROS1, and RET fusion assays in 198 consecutively resected lung adenocarcinomas from never-smoker females at a single institution. EGFR mutation, which was the most frequent driver gene mutation, was detected in 124 (63%) cases. Mutation of ALK, KRAS, PIK3CA, ERBB2, BRAF, ROS1, and RET genesoccurred in 7%, 4%, 2.5%, 1.5%, 1%, 1%, and 1% of cases, respectively. Thus, 79% of lung adenocarcinomas from never-smoker females harbored well-known oncogenic mutations. Mucinous adenocarcinomas tended to have a lower frequency of known driver gene mutations than other histologic subtypes. EGFR mutation was associated with older age and a predominantly acinar pattern, while ALK rearrangement was associated with younger age and a predominantly solid pattern. Lung cancer in never-smoker Asian females is a distinct entity, with the majority of these cancers developing from oncogenic mutations.

摘要

本研究旨在确定从不吸烟的亚洲女性肺腺癌患者中已知致癌驱动基因突变的分布情况。我们使用MassARRAY LungCarta Panel以及ALK、ROS1和RET融合检测法,对来自单一机构的198例连续切除的从不吸烟女性肺腺癌患者的26个肺癌相关基因和3个融合基因中的214个突变进行了分析。最常见的驱动基因突变是EGFR突变,在124例(63%)患者中检测到。ALK、KRAS、PIK3CA、ERBB2、BRAF、ROS1和RET基因的突变分别发生在7%、4%、2.5%、1.5%、1%、1%和1%的病例中。因此,从不吸烟女性的肺腺癌中,79%存在已知的致癌突变。黏液腺癌的已知驱动基因突变频率往往低于其他组织学亚型。EGFR突变与年龄较大和主要为腺泡型有关,而ALK重排与年龄较小和主要为实体型有关。从不吸烟的亚洲女性肺癌是一种独特的疾病实体,这些癌症大多由致癌突变发展而来。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71d1/4467161/ce07eb9a50a8/oncotarget-06-5465-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71d1/4467161/63f858419362/oncotarget-06-5465-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71d1/4467161/cb6e61f67291/oncotarget-06-5465-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71d1/4467161/1909661a2166/oncotarget-06-5465-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71d1/4467161/ce07eb9a50a8/oncotarget-06-5465-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71d1/4467161/63f858419362/oncotarget-06-5465-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71d1/4467161/cb6e61f67291/oncotarget-06-5465-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71d1/4467161/1909661a2166/oncotarget-06-5465-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71d1/4467161/ce07eb9a50a8/oncotarget-06-5465-g004.jpg

相似文献

1
Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR.从不吸烟的亚洲女性肺癌是由致癌突变驱动的,其中最常见的是涉及表皮生长因子受体(EGFR)。
Oncotarget. 2015 Mar 10;6(7):5465-74. doi: 10.18632/oncotarget.2925.
2
Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.东亚从不吸烟肺腺癌的致癌驱动基因突变谱。
PLoS One. 2011;6(11):e28204. doi: 10.1371/journal.pone.0028204. Epub 2011 Nov 30.
3
Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.女性非吸烟亚洲肺腺癌患者的驱动基因突变分析。
Cell Biochem Biophys. 2012 Nov;64(2):155-60. doi: 10.1007/s12013-012-9384-8.
4
Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.女性从不吸烟者肺腺癌中驱动基因突变的频率随组织学亚型和诊断时的年龄而变化。
Clin Cancer Res. 2012 Apr 1;18(7):1947-53. doi: 10.1158/1078-0432.CCR-11-2511. Epub 2012 Feb 8.
5
Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.东亚从不吸烟人群的肺腺癌是一种主要由可靶向的致癌基因突变激酶定义的疾病。
J Clin Oncol. 2010 Oct 20;28(30):4616-20. doi: 10.1200/JCO.2010.29.6038. Epub 2010 Sep 20.
6
Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.吸烟者肺腺癌中明确的致癌驱动基因突变的频率因组织学亚型和分级吸烟剂量而异。
Lung Cancer. 2013 Jan;79(1):8-13. doi: 10.1016/j.lungcan.2012.09.018. Epub 2012 Oct 23.
7
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.瑞士东北部肺腺癌患者致癌驱动基因突变频率分析及其与临床病理特征的相关性
Diagn Pathol. 2019 Feb 11;14(1):18. doi: 10.1186/s13000-019-0789-1.
8
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.比较东亚人群中 ROS1 融合与其他驱动基因突变的肺腺癌患者的临床和预后特征。
J Thorac Oncol. 2014 Aug;9(8):1171-9. doi: 10.1097/JTO.0000000000000232.
9
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.中国非小细胞肺癌中靶向下一代测序鉴定的驱动基因的基因组特征。
Oncologist. 2019 Nov;24(11):e1070-e1081. doi: 10.1634/theoncologist.2018-0572. Epub 2019 Mar 22.
10
Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.多靶点检测评估日本肺腺癌患者的基因突变谱:一项前瞻性、单中心研究。
Cancer. 2014 May 15;120(10):1471-81. doi: 10.1002/cncr.28604. Epub 2014 Apr 3.

引用本文的文献

1
Characterization of Mutational Signatures in Tumors from a Large Chinese Population.中国大规模人群肿瘤中突变特征的表征
Cancer Res Commun. 2025 Aug 1;5(8):1466-1476. doi: 10.1158/2767-9764.CRC-24-0496.
2
Sex, hormones, and lung health.性别、激素与肺部健康。
Physiol Rev. 2025 Aug 6. doi: 10.1152/physrev.00026.2024.
3
Precision Medicine in Lung Cancer Screening: A Paradigm Shift in Early Detection-Precision Screening for Lung Cancer.肺癌筛查中的精准医学:早期检测的范式转变——肺癌精准筛查

本文引用的文献

1
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.利用肺癌致癌驱动基因的多重分析来选择靶向药物。
JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741.
2
Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.与从不吸烟的肺腺癌患者中 ALK 重排相关的临床特征。
Lung Cancer. 2014 Feb;83(2):259-64. doi: 10.1016/j.lungcan.2013.11.009. Epub 2013 Nov 20.
3
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).
Diagnostics (Basel). 2025 Jun 19;15(12):1562. doi: 10.3390/diagnostics15121562.
4
Lung Cancer incidence in both sexes across global areas: data from 1978 to 2017 and predictions up to 2035.全球各地区男女肺癌发病率:1978年至2017年的数据及至2035年的预测
BMC Pulm Med. 2025 Jun 4;25(1):281. doi: 10.1186/s12890-025-03748-0.
5
Obesity's Disparate Impact on COVID-19 Outcomes in Asian American Patients with Cancer.肥胖对亚裔美国癌症患者新冠病毒病结局的不同影响
medRxiv. 2025 May 16:2025.05.14.25327577. doi: 10.1101/2025.05.14.25327577.
6
Potential Influence of Genetic Variants and Expression Levels on the Mutation Status and Disease Progression in Patients with Lung Adenocarcinoma.基因变异和表达水平对肺腺癌患者突变状态及疾病进展的潜在影响
Int J Mol Sci. 2025 May 11;26(10):4606. doi: 10.3390/ijms26104606.
7
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy.非小细胞肺癌进展及对治疗反应中的肿瘤与微环境相互作用
Nat Rev Clin Oncol. 2025 May 16. doi: 10.1038/s41571-025-01021-1.
8
Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions.探索抗体药物偶联物在脑转移瘤和原发性脑肿瘤中的作用:见解与未来方向
Cancers (Basel). 2025 May 7;17(9):1591. doi: 10.3390/cancers17091591.
9
PI3K and PINK1 Immunoexpression as Predictors of Survival in Patients Undergoing Resection of Brain Metastases from Lung Adenocarcinoma.PI3K和PINK1免疫表达作为肺腺癌脑转移瘤切除患者生存的预测指标
Int J Mol Sci. 2025 Mar 24;26(7):2945. doi: 10.3390/ijms26072945.
10
Clinical application of liquid biopsy genomic profiling in NSCLC: Asian perspectives.液体活检基因组分析在非小细胞肺癌中的临床应用:亚洲视角
J Liq Biopsy. 2023 Dec 12;3:100131. doi: 10.1016/j.jlb.2023.100131. eCollection 2024 Mar.
非小细胞肺癌中的突变发生率和一致性:基于种族和组织学的荟萃分析(mutMap)。
Ann Oncol. 2013 Sep;24(9):2371-6. doi: 10.1093/annonc/mdt205. Epub 2013 May 30.
4
KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma.KRAS 突变与肺腺癌的实体生长模式和肿瘤浸润白细胞有关。
Mod Pathol. 2013 Oct;26(10):1307-19. doi: 10.1038/modpathol.2013.74. Epub 2013 Apr 26.
5
Cancer genes in lung cancer: racial disparities: are there any?肺癌中的癌症基因:种族差异:存在吗?
Genes Cancer. 2012 Jul;3(7-8):467-80. doi: 10.1177/1947601912465177.
6
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.不吸烟女性肺腺癌中 EGFR 突变或 ALK 重排与 DNA 修复和合成基因表达的相关性。
Cancer. 2012 Nov 15;118(22):5588-94. doi: 10.1002/cncr.27603. Epub 2012 May 8.
7
KIF5B-RET fusions in lung adenocarcinoma.肺腺癌中的 KIF5B-RET 融合。
Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644.
8
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.阿法替尼(BIBW 2992)在 HER2/neu 激酶结构域突变的肺腺癌患者中的临床活性。
Lung Cancer. 2012 Apr;76(1):123-7. doi: 10.1016/j.lungcan.2012.01.008. Epub 2012 Feb 10.
9
Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.女性从不吸烟者肺腺癌中驱动基因突变的频率随组织学亚型和诊断时的年龄而变化。
Clin Cancer Res. 2012 Apr 1;18(7):1947-53. doi: 10.1158/1078-0432.CCR-11-2511. Epub 2012 Feb 8.
10
ROS1 rearrangements define a unique molecular class of lung cancers.ROS1 重排定义了一类独特的肺癌分子亚型。
J Clin Oncol. 2012 Mar 10;30(8):863-70. doi: 10.1200/JCO.2011.35.6345. Epub 2012 Jan 3.